News | April 13, 2026
Unichem’s US arm recalls Buspirone tablets after stability test OOS result
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
No adverse events reported; recall involves 5 mg 500-count bottles in the US market
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Subscribe To Our Newsletter & Stay Updated
